Member Info for Lebus

Or he simply tells it as it is more likely. Two decades of relying on other peoples money to stay afloat, no product as yet, no immediate prospect of a product being licensed, and a sp down from around 200p to 20p in less than 12 months. All fact.

“Nothing has changed” Er.. what about sp down by 11% already today. That’s a change

And others will still be berating those who are even mildly critical of the state this business is in after nearly two decades of spending our money

Market celebrates a good news week for Sgn. Sp now hovering around 20p. But hey, at least we have the financial update in just under a week. That should really light the touch paper.

Dunk - no harm in treating other posters with a little respect, surely? What you know about other contributors is limited to what others are prepared to divulge. You make speculations and claim them to be facts.

Longer term, maybe Paladin. Short term though, and If no positive news pre half year results next week, sp likely to take yet another minimum 10% hit in my view. We need news that impacts on funding going forward to avoid further declines in value post results day

Derampers trying to create negative sentiment? No Tommy, it’s the sp creating negative sentiment - from over £2 to under 20p in less than a year on the back of a botched trial

Yes, these things do take time AJ. But shouldn’t two decades be long enough for a serious commercial enterprise with a product that SH told us, “we know it works”. More trials needed because the last one failed to achieve end points - simple as.

And still, those who make even the slightest crisis of this shambles of a business are derided as de rampers or doom mongers. A botched phase 3 trial, a drop in sp from around 200p to just over 20p in 6 months, and it’s just a business as usual attitude, jam tomorrow blah blah blah

Yep.A deep dive into 2 years old data. No rush then.

Could this interview have taken place pre Feb 2022 and dela in publishing? Doesn’t really fit in with the known narrative otherwise

The Pallidin. With respect, those posters who are critical of A business yet to bring a product to market and fully reliant on investors to keep it solvent after nearly two decades, might better be referred to as realists rather than cynics. Best regards

Manifesto - I have no idea about your personal investment strategy. In any event it is absolutely none of my business. Similarly, you have no idea about my financial interest in Synairgen, and it is none of your business. No need for me to comment further on your arrogant presumptions

Im sure that I’m not the only one thinking that after almost two decades Synairgen should already have a comprehensive understanding of acute respiratory viral infection. Prof Holgate told us, “we know it works” but further observations now required nonetheless. Sorry but I find this announcement more disappointing than uplifting.

I recall Brooke Clarke indicating that she was going on holiday and would not be responding to any emails sent whilst she was away, both during her break and following her return to work.

If you dared to open your eyes Manifesto you might notice that this business is now valued at around 24p per share as opposed to 175p when investors last responded to a cash call. Many false promises and a botched trial later, the business is worth no more than it was worth 15 years ago. Meanwhile the fat cats continue to draw their outrageous salaries.

Anticipating the sell up and jog on then reply, I dare not. I am sitting on a huge paper loss. If, and it’s a big if, Synairgen is included in the Strive programme we will see a temporary re-rating at least, and that will be the time for me to get rid. If no Strive or other platform trial declared by the year end, I’ll take the hit and move on

Spot on Palladin. And whilst the intolerant rampers attack any posts perceived to be critical of a business yet to bring a product to market after almost two decades of spending other peoples money, the sp continues to weaken as investor confidence wanes

My sentiments too. For long term holders still nursing a 95% paper loss due to yet another trial failure, the relentless positivity that some posters expect of others is at best irritating. It is a case of business as usual as far as the CEO and Board is concerned. They get rich and investors have financed their nice little packages for almost 2 decades now. Fat cats

Agreed Costs. And whilst appreciating the range of questions investors need to raise tomorrow, the analysts will focus on one critical theme. When will your cash run out and how do you continue as a business without a further cash raise at a massively diluted price

My cash position ceased to be positive on 21st February. It is currently about 85% negative. Still hoping for a RNS with positive news re platform trial/ JV prior to AGM. Failing that, the analysts will have a laser like focus on cash left to finance operations whilst waiting for a clear path forward to be arranged

Spot on Aether